Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 403,162 shares at $43.88 ($4.6M) on 2021-12-29, disclosed to the SEC on 2021-12-30.
Open-market sale of $4.6M DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 300,000 | $0 | 0.0% |
| 2 | $44.37 | 3,732 | $166K | 3.6% |
| 3 | $44.37 | 3,732 | $166K | 3.6% |
| 4 | $44.37 | 3,646 | $162K | 3.5% |
| 5 | $44.37 | 3,646 | $162K | 3.5% |
| 6 | $44.38 | 3,602 |
| $160K |
| 3.5% |
| 7 | $44.38 | 3,602 | $160K | 3.5% |
| 8 | $43.87 | 10,700 | $469K | 10.2% |
| 9 | $43.88 | 10,704 | $470K | 10.2% |
| 10 | $43.88 | 10,700 | $470K | 10.2% |
| 11 | $43.88 | 10,704 | $470K | 10.2% |
| 12 | $45.13 | 3,343 | $151K | 3.3% |
| 13 | $45.13 | 3,343 | $151K | 3.3% |
| 14 | $45.31 | 5,625 | $255K | 5.5% |
| 15 | $45.31 | 5,625 | $255K | 5.5% |
| 16 | $45.31 | 6,002 | $272K | 5.9% |
| 17 | $45.31 | 6,002 | $272K | 5.9% |
| 18 | $45.59 | 3,377 | $154K | 3.4% |
| 19 | $45.59 | 3,377 | $154K | 3.4% |
| 20 | $45.71 | 900 | $41K | 0.9% |
| 21 | $45.72 | 800 | $37K | 0.8% |
| Total | $11.39 avg | 403,162 | $4.6M | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |